Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation. A modelling analysis from the Euro Heart Survey.

In conclusion, based on this modelling exercise, the utilisation of apixaban and dabigatran for thromboprophylaxis could provide a profound annual mathematical net clinical benefit on stroke and major bleeds, in European AF patients. PMID: 23179181 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/PubMed/23179181?dopt=Abstract

Source: Thrombosis and Haemostasis - November 22, 2012 Category: Hematology Authors: Pisters R, Nieuwlaat R, Lane DA, Crijns HJ, Lip GY Tags: Thromb Haemost Source Type: research